Efficacy and safety of visepegenatide, a long-acting weekly GLP-1 receptor agonist as monotherapy in type 2 diabetes mellitus: a randomised, double-blind, parallel, placebo-controlled phase 3 trial
Titel:
Efficacy and safety of visepegenatide, a long-acting weekly GLP-1 receptor agonist as monotherapy in type 2 diabetes mellitus: a randomised, double-blind, parallel, placebo-controlled phase 3 trial
Auteur:
Yan, Xiang Ma, Jianhua Liu, Yan Wang, Xuhong Li, Sheli Yan, Shuang Mo, Zhaohui Zhu, Yikun Lin, Jingna Liu, Jie Jia, Ying Liu, Li Ding, Ke Xu, Michael Zhou, Zhiguang